{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:05:02Z","timestamp":1789625102588,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Rhabdomyolysis (RM) may cause acute kidney injury (AKI), but the classic triad of myalgia, muscle weakness, and dark-colored urine is often absent. Fenofibrate-associated RM is rare and may be overlooked in older patients with chronic kidney disease (CKD), reduced renal reserve, or polypharmacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 70-year-old man with CKD was admitted with nausea, poor appetite, and a marked increase in serum creatinine for 1 week. Two months earlier, atorvastatin had been discontinued, and micronized fenofibrate had been started for hypertriglyceridemia. He had no obvious myalgia, muscle weakness, or dark-colored urine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Serum creatinine rapidly increased from approximately 130 \u03bcmol\/L to 1132\u20131202 \u03bcmol\/L. Peak creatine kinase (CK) was 28,831 U\/L, and serum myoglobin was 915\u2009ng\/mL, accompanied by metabolic acidosis, hypocalcemia, and hyperphosphatemia. Based on the temporal association with fenofibrate exposure, marked muscle enzyme elevation, improvement after drug withdrawal, and absence of common alternative triggers, the patient was diagnosed with probable fenofibrate-associated rhabdomyolysis complicated by KDIGO stage 3 AKI superimposed on underlying CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Fenofibrate was discontinued immediately. The patient received fluid therapy, correction of metabolic acidosis, electrolyte monitoring and management, and supportive kidney care. Because he initially refused dialysis, intermittent hemodialysis (IHD) was initiated on hospital day 10 for persistent uremic symptoms, severe AKI, and metabolic derangements. Net ultrafiltration was set at 0\u2009mL to avoid further volume depletion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>After IHD and supportive treatment, gastrointestinal symptoms improved, urine output increased, and CK and renal function gradually improved. Dialysis frequency was reduced after discharge, and IHD was discontinued 5 weeks later. At 8 months after discharge, serum creatinine had decreased to 157 \u03bcmol\/L, and CK and myoglobin remained normal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>In older patients with CKD, eGFR should be calculated before fenofibrate is prescribed, and dosing should follow the product label. Unexplained renal deterioration or nonspecific symptoms after fenofibrate exposure should prompt measurement of CK and myoglobin. Immediate drug withdrawal and supportive treatment are essential, whereas IHD should be reserved for standard AKI indications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050337","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:06:47Z","timestamp":1787332007000},"page":"e50337","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Fenofibrate-associated rhabdomyolysis complicated by dialysis-requiring acute kidney injury presenting with atypical clinical manifestations"],"prefix":"10.1097","volume":"105","author":[{"given":"Yumei","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Nephrology, The First People\u2019s Hospital of Lin\u2019an District, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8798-7558","authenticated-orcid":false,"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First People\u2019s Hospital of Lin\u2019an District, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260917","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra0801327","article-title":"Rhabdomyolysis and acute kidney injury.","volume":"361","author":"Bosch","year":"2009","journal-title":"N Engl J Med"},{"key":"R2-20260917","doi-asserted-by":"crossref","first-page":"e000836","DOI":"10.1136\/tsaco-2021-000836","article-title":"Rhabdomyolysis: an American association for the surgery of trauma critical care committee clinical consensus document.","volume":"7","author":"Kodadek","year":"2022","journal-title":"Trauma Surg Acute Care Open"},{"key":"R3-20260917","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.3390\/jcm14196892","article-title":"Predicting acute kidney injury in acute rhabdomyolysis.","volume":"14","author":"Lim","year":"2025","journal-title":"J Clin Med"},{"key":"R4-20260917","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.clinthera.2025.09.010","article-title":"Characterizing fenofibrate-related renal and urinary adverse events: a comprehensive analysis of FDA adverse event reporting system database.","volume":"47","author":"Wang","year":"2025","journal-title":"Clin Ther"},{"key":"R5-20260917","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1515\/DMDI.2007.22.4.279","article-title":"Hypothyroidism is a predisposing factor for fenofibrate-induced rhabdomyolysis--patient report and literature review.","volume":"22","author":"Satarasinghe","year":"2007","journal-title":"Drug Metabol Drug Interact"},{"key":"R6-20260917","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/08860220701573640","article-title":"Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis.","volume":"29","author":"Tahmaz","year":"2007","journal-title":"Ren Fail"},{"key":"R7-20260917","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2169\/internalmedicine.47.0939","article-title":"Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients.","volume":"47","author":"Unal","year":"2008","journal-title":"Intern Med"},{"key":"R8-20260917","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1590\/S0004-27302009000300015","article-title":"Fenofibrate-induced rhabdomyolysis in a patient with chronic kidney disease: an unusual presenting feature of hypothyroidism.","volume":"53","author":"de Sousa","year":"2009","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"R9-20260917","doi-asserted-by":"crossref","first-page":"537818","DOI":"10.1155\/2010\/537818","article-title":"Rhabdomyolysis-induced acute renal failure following fenofibrate therapy: a case report and literature review.","volume":"2010","author":"Danis","year":"2010","journal-title":"Case Rep Med"},{"key":"R10-20260917","first-page":"371","article-title":"Acute renal failure due to fenofibrate monotherapy.","volume":"11","author":"Uskudar Cansu","year":"2011","journal-title":"Anadolu Kardiyol Derg"},{"key":"R11-20260917","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1159\/000331559","article-title":"Rhabdomyolysis associated with fenofibrate monotherapy in a patient with chronic myelogenous leukemia.","volume":"5","author":"Kato","year":"2011","journal-title":"Case Rep Gastroenterol"},{"key":"R12-20260917","first-page":"849","article-title":"Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus.","volume":"62","author":"Soyoral","year":"2012","journal-title":"J Pak Med Assoc"},{"key":"R13-20260917","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.clinbiochem.2011.09.025","article-title":"Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report.","volume":"45","author":"Erdur","year":"2012","journal-title":"Clin Biochem"},{"key":"R14-20260917","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4103\/0253-7613.111912","article-title":"A case of rhabdomyolysis complicated with acute renal failure after resumption of fenofibrate therapy: a first report.","volume":"45","author":"Kiskac","year":"2013","journal-title":"Indian J Pharmacol"},{"key":"R15-20260917","first-page":"249","article-title":"Fenofibrate-induced rhabdomyolysis in an adolescent with chronic renal failure and hypothyroidism.","volume":"28","author":"Marques","year":"2014","journal-title":"Port J Nephrol Hypert"},{"key":"R16-20260917","doi-asserted-by":"crossref","first-page":"e0318","DOI":"10.1097\/MD.0000000000010318","article-title":"Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: a rare case report and literature review.","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"R17-20260917","doi-asserted-by":"crossref","first-page":"e20390","DOI":"10.1097\/MD.0000000000020390","article-title":"Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: a rare case report and a review of the literature.","volume":"99","author":"Zhou","year":"2020","journal-title":"Medicine (Baltim)"},{"key":"R18-20260917","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.nmd.2014.05.005","article-title":"Rhabdomyolysis: review of the literature.","volume":"24","author":"Zutt","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"1 Pt A","key":"R19-20260917","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.amjsurg.2021.11.022","article-title":"Management of rhabdomyolysis: a practice management guideline from the Eastern Association for the Surgery of Trauma.","volume":"224","author":"Sawhney","year":"2022","journal-title":"Am J Surg"},{"key":"R20-20260917","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/cc13897","article-title":"Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review.","volume":"18","author":"Petejova","year":"2014","journal-title":"Crit Care"},{"key":"R22-20260917","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000551559","article-title":"Rhabdomyolysis-associated acute kidney injury: from pathogenic mechanisms to the therapeutic use of sorbents.","volume":"55","author":"Naso","year":"2026","journal-title":"Blood Purif"},{"key":"R23-20260917","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/ckj\/sfv041","article-title":"Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series.","volume":"8","author":"Waheed","year":"2015","journal-title":"Clin Kidney J"},{"key":"R24-20260917","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology solution set oversight committee.","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R25-20260917","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"105","year":"2024","journal-title":"Kidney Int"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:00:48Z","timestamp":1789624848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050337"}},"subtitle":["A case report and literature review"],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":24,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050337","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"2026-06-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}